TechSeeker Profile

Corixa Corporation (AKA: Iasys Corporation)
Profile last edited on: 9/11/2013

Immunotherapeutic products
TS Type
Small Corp
Status
Acquired
Year Founded
1994
Last Involved Year
1999

Key People / Management

Location Information

1900 9th Avenue Suite 1100
Seattle, WA 98104
   (206) 366-3700
   www.Corixa.com

Public Profile

In July 2005 Corixa Corporation was acquired by GlaxoSmithKline plc. with the firm formally closing down in 2006. Previously called Iasys Corporation (changed in FY 95), Corixa Corporation had been a research-based biotechnology company, primarily engaged in the research, development, and commercialization of products useful in preventing, treating or diagnosing cancer, certain infectious diseases and certain autoimmune diseases. With a lab and production facility also in Montana, Corixa Corporation developed immunotherapeutic products that address various infectious and inflammatory diseases, allergies, and cancers. The company initially focused on developing cancer therapies, but its success with vaccine adjuvants (additives that boost the immune system) has led the firm to change course.The company provided Adjuvants, which boosts the body’s immune response; and TLR4 Agonists and Antagonists, which interacts with body’s immune system and initiates the body’s innate immune response. Its Adjuvants in vaccines protect against diseases, including hepatitis B, cervical cancer, genital herpes, malaria, tuberculosis, lung cancer, allergy, and breast cancer. The company’s Agonists include immune agents for seasonal allergic rhinitis, stimulating resistance to viral and bacterial pathogens, and for perennial rhinitis. Its Antagonists are used as an anti-inflammatory compound in IBD and other inflammatory disease indications.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
200
Revenue
N/A
Public/Private
Publicly Traded
Stock Info
NASDAQ : CRXA
Received SBIR $$
Yes

Techseeker firm in the news

There are no news available.